Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Boshuizen J, Pencheva N, Krijgsman O, Altimari DD, Castro PG, de Bruijn B, Ligtenberg MA, Gresnigt-Van den Heuvel E, Vredevoogd DW, Song JY, Visser N, Apriamashvili G, Janmaat ML, Plantinga TS, Franken P, Houtkamp M, Lingnau A, Jure-Kunkel M, Peeper DS. Boshuizen J, et al. Among authors: lingnau a. Cancer Res. 2021 Apr 1;81(7):1775-1787. doi: 10.1158/0008-5472.CAN-20-0434. Epub 2021 Feb 2. Cancer Res. 2021. PMID: 33531370
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
Koopman LA, Terp MG, Zom GG, Janmaat ML, Jacobsen K, Gresnigt-van den Heuvel E, Brandhorst M, Forssmann U, de Bree F, Pencheva N, Lingnau A, Zipeto MA, Parren PW, Breij EC, Ditzel HJ. Koopman LA, et al. Among authors: lingnau a. JCI Insight. 2019 Nov 1;4(21):e128199. doi: 10.1172/jci.insight.128199. JCI Insight. 2019. PMID: 31600169 Free PMC article.
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.
Overdijk MB, Strumane K, Beurskens FJ, Ortiz Buijsse A, Vermot-Desroches C, Vuillermoz BS, Kroes T, de Jong B, Hoevenaars N, Hibbert RG, Lingnau A, Forssmann U, Schuurman J, Parren PWHI, de Jong RN, Breij ECW. Overdijk MB, et al. Among authors: lingnau a. Mol Cancer Ther. 2020 Oct;19(10):2126-2138. doi: 10.1158/1535-7163.MCT-20-0044. Epub 2020 Aug 26. Mol Cancer Ther. 2020. PMID: 32847982
93 results